1.97

2.07% 0.04

After Hours: 1.91 -0.06 -3.05%

Annovis Bio Inc (ANVS)

Overview News Price History Why ANVS Down? Discussions Forecast

Annovis Bio Inc stock is traded at $1.97, with a volume of 455.58K. It is up +2.07% in the last 24 hours and up +4.23% over the past month. Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

Previous Close:

$1.93

Open:

$1.96

24h Volume:

455.58K

Relative Volume:

0.39

Market Cap:

$83.81M

Revenue:

Net Income/Loss:

$-40.92M

P/E Ratio:

-1.1476

EPS:

-1.7167

Net Cash Flow:

$-26.53M

1W Performance:

+5.91%

1M Performance:

+4.23%

6M Performance:

-48.83%

1Y Performance:

-16.53%

1-Day Range:

$1.91

$1.99

1-Week Range:

$1.83

$2.02

52-Week Range:

$1.5407

$5.50

Annovis Bio Inc Stock (ANVS) Company Profile

Name

Annovis Bio Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

484-875-3192

Address

101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

ANVS's Discussions on Twitter

Compare ANVS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANVS Annovis Bio Inc	1.97	79.13M	0	-40.92M	-26.53M	-1.7167
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-10-25	Downgrade	D. Boral Capital	Buy → Hold
Oct-25-24	Upgrade	Maxim Group	Hold → Buy
Dec-29-23	Initiated	Canaccord Genuity	Buy
Jul-07-21	Reiterated	Maxim Group	Buy

Annovis Bio Inc Stock (ANVS) Latest News

Jul 01, 2026

Annovis Bio promotes Cheng Fang to chief scientific officer - Investing.com

Jul 01, 2026

Annovis Bio Promotes Cheng Fang to Chief Scientific Officer Ahead of Phase 3 Milestones - citybiz

Jul 01, 2026

Annovis Bio promotes Cheng Fang to chief scientific officer By Investing.com - Investing.com Canada

Jul 01, 2026

Annovis elevates its R&D chief as Phase 3 Alzheimer’s data nears - Stock Titan

Jul 01, 2026

Jun 30, 2026

ANVSAnnovis Bio Inc Latest SEC Filings - Finviz

Jun 30, 2026

Jun 29, 2026

ANVS Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineAnalyst Consensus Shift - dars.gov.et

Jun 29, 2026

Annovis Bio, Inc.(NYSE: ANVS) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Annovis Bio, Inc.(NYSE: ANVS) added to Russell 3000E Index - marketscreener.com

Jun 29, 2026

Annovis Bio, Inc.(NYSE: ANVS) added to Russell Microcap Index - marketscreener.com

Jun 29, 2026

Jun 28, 2026

ANVS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Jun 28, 2026

Annovis Bio, Inc.(NYSE: ANVS) added to Russell Microcap Growth Benchmark Index - marketscreener.com

Jun 28, 2026

Jun 27, 2026

Annovis Bio (ANVS) Shows Resilience With 4.24% Gain, Testing Key ResistancePost-Earnings Moves - dars.gov.et

Jun 27, 2026

Annovis Bio | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo

Jun 27, 2026

Jun 26, 2026

Enterprise value to EBITDA forward of Annovis Bio, Inc. – NYSE:ANVS - TradingView

Jun 25, 2026

Price to sales forward of Annovis Bio, Inc. – NYSE:ANVS - TradingView

Jun 25, 2026

Enterprise value to revenue forward of Annovis Bio, Inc. – NYSE:ANVS - TradingView

Jun 25, 2026

Jun 21, 2026